Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06973187 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 3
Development phase
500
Enrollment target
20
Study locations

NCT06973187: Recruiting Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeOne Medicines.

NCT06973187 is a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 500 participants, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06973187, a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 3
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

Primary Outcome

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions

  • DRUG BGB-16673
  • DRUG Pirtobrutinib

Study Locations (20)

California

  • University of California San Diego (Ucsd) Moores Cancer Center - La Jolla
  • UCLA Department of Medicine Hematologyoncology - Los Angeles
  • Stanford Cancer Institute - Palo Alto

Florida

  • Cancer Specialists of North Florida - Jacksonville
  • Mayo Clinic Jacksonville - Jacksonville
  • Mount Sinai Comprehensive Cancer Center - Miami Beach

Louisiana

  • Our Lady of the Lake Hospital - Baton Rouge
  • Mary Bird Perkins Cancer Center - Baton Rouge
  • Ochsner Clinic Foundation - New Orleans

New York

  • Memorial Sloan Kettering Cancer Center Mskcc - New York
  • University of Rochester - Rochester

Arizona

  • Mayo Clinic Phoenix - Phoenix

Delaware

  • Christiana Care - Newark

Kansas

  • The University of Kansas Cancer Center - Westwood

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-09-04
Est. Completion 2028-04-17
Phase Phase 3
BeOne Medicines

29 total trials

What NCT06973187 shows while recruiting

NCT06973187 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (179% higher).

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which BGB-16673 is the first listed.

NCT06973187 names 20 study sites across 13 states, led by California, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT06973187 about?

NCT06973187 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase ...

What is the current status of trial NCT06973187?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-09-04. Estimated completion is 2028-04-17.

What conditions does trial NCT06973187 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT06973187?

The interventions under investigation include: BGB-16673 (DRUG), Pirtobrutinib (DRUG).

Who is sponsoring clinical trial NCT06973187?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06973187 being conducted?

This trial has 20 study locations across Arizona, California, Delaware, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06973187's enrollment target sits among peer trials

500 21st of 187 higher than 166 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06973187

Source: ClinicalTrials.gov NCT06973187, the US trial registry maintained by the National Library of Medicine. NCT06973187 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.